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CONCISE COMMUNICATION
Factors associated with short-term changes in
HIV viral load and CD4R cell count in
antiretroviral-naive individuals
The Natural History Project Working GroupM for the Collaboration
of Observational HIV Epidemiological Research Europe (COHERE)M
in EuroCoordM
Objectives: Among antiretroviral therapy (ART)-naive individuals, viral load levels
tend to increase and CD4þ cell counts decline over time. We sought to explore the rate
of change and influence of other factors associated with these markers of HIV
progression.
Design: An observational cohort collaboration study.
Methods: A total of 158385 pairs of consecutive viral load and CD4þ cell count
simultaneously measured from 34384 ART-naive individuals in the COHERE database
were analysed. Annual changes and factors associated with these changes were
estimated using generalized estimating equations.
Results: Viral load continued to rise at a mean [95% confidence interval (CI)] rate of
0.091 (0.086–0.096) log10 copies/ml per year. A faster rise in viral loadwas significantly
associated with older age, such that for every 10 years older, it was a mean 0.022
log10 copies/ml per year greater. The mean (95% CI) CD4
þ cell count change was
78.0 (80.1 to 76.0) cell/ml per year and it was strongly associated with a higher
current viral load: for every 1 log10 copies/ml higher, CD4
þ cell count declined by an
additional 37.6 cells/ml per year (P<0.001). Current viral load was a stronger predictor
of CD4þ cell count depletion than baseline viral load. Neither sex, race nor trans-
mission by injecting drug use was associated with change in either the viral load or
CD4þ cell count.
Discussion: We found that in ART-naive individuals, viral load continues to increase
over time and more sharply in those who are older. Our results also suggest that higher
current viral load is strongly associated with ongoing rate of CD4þ cell count depletion.
 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2014, 28:1351–1356
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Introduction
HIV infection in antiretroviral therapy (ART)-naive
individuals is typically characterized by a rise in plasma
HIV RNA (viral load) and a decline in CD4þ cell count.
If left untreated, this eventually leads to opportunistic
infections, development of AIDS and AIDS-related
deaths [1–4]. Although viral load and CD4þ cell count
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are well established prognostic markers of HIV disease
progression [2,5,6], some uncertainties remain over the
rate of change of viral load prior to starting ART and the
relationship with change in CD4þ cell count [7]. A full
description of HIV natural history in terms of these
markers is important because these are used to guide
clinical decisions such as timing of ART initiation [7].
Furthermore, comprehensive data on viral load and
CD4þ cell count changes are necessary to inform the
structure and parameterization of mathematical models of
HIV [8,9]. Here, we generate more precise estimates
relating to factors associated with short-term pre-ART
changes in viral load and CD4þ cell count in a large
cohort collaboration.
Methods
Study population
The Collaboration of Observational HIV Epidemiolo-
gical Research Europe (COHERE) is a collaboration of
36 HIV cohorts within the EuroCoord (www.Euro-
Coord.net) network [10].
Statistical methods
All available viral load and CD4þ cell count measure-
ments from HIV-positive adults (aged >16 years)
participating in the COHERE study measured prior to
ART initiation were considered. We included pairs of
consecutive viral load and CD4þ cell count values
measured between 60 and 365 days apart. The time of the
first measurement of the pair is termed t0 and the second,
t1. Viral load measurements were required to be measured
within 1 week of each of the two CD4þ cell count
measurements. Three consecutive viral load and CD4þ
cell count measurements were required per individual for
study inclusion, so that the measurement taken prior to
the pair (at time t-1) could be included as an additional
covariate in the model to minimize biases due to
regression to the mean. Pairs were excluded if the
difference between consecutive viral load measurements
was greater than 0.8 log10 copies/ml (due to suspected
data errors related to unrecorded ART-use) or if CD4þ
cell count at t0 was less than 100 cells/ml (because there is
less scope for decline).
Factors associated with short-term viral load and CD4þ
cell count changes were evaluated using linear regression
with an autoregressive correlation structure and gener-
alized estimating equations to take into account repeated
measures per individual. The response variable was the
annualized change in measurement, that is, [(measure-
ment at t1 – measurement at t0) 365]/(t1 – t0). Covari-
ates of interest were current viral load (only in CD4þ cell
count change analysis), current CD4þ cell count (only in
viral load change analysis), current age, sex, race and
whether likely route of HIV transmission was injection
drug use (IDU-transmission). ‘Current’ was defined as
at t0.
In a subanalysis, we investigated the effect of baseline viral
load and current viral load on CD4þ cell count changes.
Baseline for each patient was defined as the first date on
which both viral load and CD4þ cell count were
available. In this subanalysis, pairs of CD4þ cell counts
were included only if viral load at t0 was measured at least
1 year from baseline.
The sensitivity of results was first assessed by fitting mixed
models. In another sensitivity analysis, calendar year
(linearly and using 5-year categories) was included as an
additional covariate. The CD4þ cell count models used
the absolute scale for CD4þ cell count for ease of
interpretation, but we also considered CD4þ cell count
transformed to the square root scale (wherein the
assumption of normality is more likely to hold). As the
inclusion criteria would result in inclusion of fewer pairs
from individuals started on ART earlier (i.e. fast
progressors), we carried out a further sensitivity analysis
in which only the first pair per person was included.
Finally, we excluded pairs of observations in which the
difference between consecutive viral load measurements
was greater than 1.5 log10 copies/ml (as opposed to 0.8
log10 copies/ml in the main analysis).
All analyses were performed using SAS software, Version
9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Descriptive analyses
We included 34 384 individuals who contributed 158 385
pairs of viral load and corresponding CD4þ cell count
measurements between 1984 and 2011. The median
number of pairs of observations per person was three
(interquartile range, IQR: 2–7). The median time
between consecutive viral load and CD4þ cell count
measurements was 4 (3–5) months. At baseline, median
age, viral load and CD4þ cell count were 34 (28–40)
years, 4.0 (2.7–4.7) log10 copies/ml and 477 (362–625)
cells/ml, respectively. Demographic characteristics of
individuals were as follows: 73% male, HIV transmission
route: MSM (47%), heterosexual (34%), IDU (12%),
other/unknown (7%) and race: black (5%), white (34%)
and other/unknown (61%).
Mean (95% confidence interval, 95% CI) change in viral
load was 0.091 (0.086–0.096) log10 copies/ml per year
(median: 0; IQR: 0.41 to þ0.64) and mean change in
CD4þ cell count was 78.0 (80.1 to 76.0) cells/ml
per year (median: 73.1; IQR: 273 to þ114). Both
changes were non-zero (P< 0.001). Median viral load
and CD4þ cell count at t0 across all pairs were 4.1
log10 copies/ml and 463 cells/ml, respectively.
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Rise in viral load
Estimated increases in viral load were significantly greater
in older people (P< 0.001) at an additional 0.022 (95%
CI, 0.017–0.027) log10 copies/ml per year greater per 10
years older (Table 1). In contrast, viral load change was
0.026 (95% CI, 0.031 to 0.021) log10 copies/ml per
year smaller for every 1 log10 copies/ml higher the viral
load at t-1. There was no evidence of an association with
sex, race or IDU-transmission. However, we did find
some evidence of an age–sex interaction (P¼ 0.03). For
example, mean viral load increase was 0.16 (95% CI,
0.12–0.20) log10 copies/ml per year in women aged
greater than 55 years, but 0.11 (95% CI, 0.09–0.14) in
men aged greater than 55 years.
Decline in CD4R cell count
Current viral load (at t0) was the strongest predictor of
CD4þ cell count decline (P< 0.001); for every 1
log10 copies/ml increase in viral load, CD4
þ cell count
declined on average by a further37.6 (95% CI,39.6 to
35.7) cells/ml per year (Table 1). The shape of this
association was considered in detail by plotting mean
CD4þ cell count change according to current viral load
(Fig. 1). The mean (95% CI) change in CD4þ cell count
varied from 5 (23 to 13) cells/ml per year if viral load
was less than 200 copies/ml, to 225 (301 to 150)
cells/ml per year if viral load was more than
1 000 000 copies/ml.
There was some evidence of a small age effect; CD4þ cell
count declined by an additional 1.7 cells/ml per year
(P¼ 0.05) per 10-year increase. This effect was found to
be even stronger (3.3 cells/ml per year decline per 10-year
increase, P< 0.001) if viral load was removed from the
statistical model. Sex, race and IDU-transmission were
not associated with CD4þ cell count decline, nor was
there any evidence of an interaction.
For pairs in which t0 was more than 1 year from baseline,
we also assessed the effects of adjusting for baseline viral
load additionally to current viral load. Median (IQR)
time from baseline to t0 was 2.6 (1.7–4.2) years. When
the model included only baseline viral load, we found that
every 1 log10 copies/ml increase in baseline viral load was
associated with an estimated14 cells/ml per year greater
CD4þ cell count decline (P< 0.001). However, when
including both baseline and current viral load, baseline
viral load was not as influential as current viral load, which
had a higher statistical significance (results not shown).
Sensitivity analyses
Similar estimates were obtained for both the viral load
change and CD4þ cell count change models when using a
mixed-model approach and also when adjusting for
calendar year (results not shown).
We also fitted a model in which all CD4þ cell count
measurements were square root-transformed. This model
(which had quasi-AIC, a goodness-of-fit statistic, 0.01
smaller) estimated the annual CD4þ cell count change
(square root scale) to be 1.83 (95% CI, 1.76 to
1.89). We found that higher viral load at t0 (P< 0.001)
and white race (P¼ 0.01) were associated with a steeper
CD4þ cell count decline. There was no evidence of an
effect of age (P¼ 0.1) or sex (P¼ 0.8).
In another sensitivity analysis in which only the first
measured pair per person was included, estimated CD4þ
cell count depletion was76.1 cells/ml per year. This was
a steeper decline than in the main analysis, in which faster
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Table 1. Factors associated with the annualised change in viral load and CD4R cell count.
Model parameter Estimate 95% CI P
Viral load model Intercepta 0.093 0.086–0.10 <0.001
Viral load at t-1 (per 1 log10 copies/ml higher) 0.026 0.031 to 0.021 <0.001
CD4þ cell count at t0 (per 100 cells/ml higher) 0.004 0.007 to 0.002 <0.001
Age at t0 (per 10 years higher) 0.022 0.017–0.027 <0.001
Female 0.004 0.006 to 0.014 0.42
Black race 0.019 0.04–0.002 0.07
Transmission by IDU 0.011 0.024 to 0.003 0.12
CD4þ cell count model Interceptb 69.0 71.8 to 66.2 <0.001
CD4þ cell count at t1 (per 100cells/ml higher) 17.0 18.1 to 15.9 <0.001
Viral load at t0 (per 1 log10 copies/ml higher) 37.6 39.6 to 35.7 <0.001
Age at t0 (per 10 years higher) 1.7 3.3 to 0.03 0.046
Female 0.8 4.2 to 2.7 0.67
Black race 2.3 3.8 to 8.3 0.48
Transmission by IDU 0.7 4.6 to 6.0 0.80
Annualized change in viral load (copies/ml, log10 scale) and CD4
þ cell count (cells/ml, absolute scale) was defined as [(measurement at
t1 – measurement at t0)365]/(t1 – t0). All continuous variables were centred, see a,bbelow), estimate sizes and 95% confidence intervals (CI) from
a multivariable linear regression model. IDU, injecting drug use.
aThe intercept in the viral load model is the annual change in viral load for an individual with viral load at t1¼4 log10 copies/ml, CD4þ cell count
at t0¼500 cells/ml, age at t0¼35 years, male, white race and transmission mode other than by IDU.
bThe intercept in the CD4þ cell count model is the annual change in CD4þ cell count for an individual with viral load at t0¼4 log10 copies/ml,
CD4þ cell count at t-1¼500cells/ml, age at t0¼35 years, male, white race and transmission mode other than by IDU.
Other comments: The reference race group is white race. All other people who were not classified as black or white race were also included in the
model but in a separate category (not shown).
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progressors were probably under-represented and there-
fore the decline was potentially underestimated. Viral
load rise was now estimated to be 0.064 log10 copies/ml
per year (instead of 0.093).
In the main analysis, 11.0% of pairs were excluded as the
difference between consecutive viral load measurements
was greater than 0.8 log10 copies/ml. In a further analysis
using 1.5 log10 copies/ml as the cut-off, 4.0% of pairs
were excluded. Results did not change considerably:
mean CD4þ cell count and viral load change were
77.6 cells/ml per year and 0.130 log10 copies/ml per
year, respectively.
Discussion
Our analyses have provided precise estimates of short-
term viral load and CD4þ cell count changes in people
who have not yet started ART and of the relationship,
or lack thereof, with age, sex, race and transmission by
IDU.
The current viral load, to a much greater degree than any
previous measure, determines the ongoing rate of CD4þ
cell count depletion. On average, the viral load continues
to rise gradually in ART-naive individuals and our
findings do not support the concept of a single ‘set-point’.
Although the ‘set-point’ is a useful concept to describe
the level at which viral load settles down to after primary
infection, the fact that levels tend to gradually increase
over time should not be overlooked [11]. Our estimate of
a mean 0.091 log10 copies/ml per year rise in viral load is
consistent with previous findings [1,11–13]. Although
this increase may seem small, the clinical relevance is
clearer on the untransformed scale: for example, an
untreated individual with a viral load of 10 000 copies/ml
who remains untreated will on average reach 12 300 and
28 500 copies/ml after 1 and 5 years, respectively.
Age was significantly associated with the change in viral
load. Faster rises were observed in older people, although
the effect size was rather small. However, there may be
potential implications for the infectiousness of older
people, who even after primary infection have higher
viral load than younger people. In this analysis, we
also found that the effect of age on CD4þ cell count
depletion seemed to be moderated by the effect of age on
viral load. Studies have previously found older age to be
strongly associated with faster CD4þ cell count decline
[5,7,14].
Our study has the advantage that, notwithstanding the
limitations mentioned below, the results should be fairly
generalizable due to the large size of the COHERE
dataset. Despite this, we did not observe any evidence of
an association between changes in the viral load and
CD4þ cell count with either sex, race or transmission
by IDU.
Limitations include that the rate of CD4þ cell count
decline was estimated in people with CD4þ cell count at
t0 greater than 100 cells/ml (although this excluded only
1354 AIDS 2014, Vol 28 No 9
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Fig. 1. Estimated CD4R cell count decline per year by viral load category at t0.
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0.7% of pairs). In addition, CD4þ cell count depletion
could have been underestimated if measurements taken
once individuals had actually started ARTwere included,
although no data indicated so (as suggested by the lowest
viral load category in Fig. 1). There may also be selection
bias due to loss to follow-up and less follow-up in people
likely to start ART earlier (e.g. people with faster CD4þ
cell count decline), although large differences in results
seem unlikely. Residual confounding of factors including
viral tropism or subtype cannot be excluded [7]. Finally,
CD4þ cell count measurements can vary appreciably [15]
and some bias due to regression to the mean may still
remain.
In this study, we found that in ART-naive individuals,
faster viral load rise was strongly associated with older age
and faster CD4þ cell count depletion was strongly
associated with a higher current viral load. These
estimates, which largely confirm previous observations
[2,11,13,14], also provide further data on factors
associated with the natural course of HIV infection
and, in particular, allow precise characterization of the
mean rate of CD4þ cell count decline to be expected
according to current viral load level.
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